UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.)
Filed by the Registrant / /
Filed by a Party other than the Registrant /X/
Check the appropriate box:
/ / Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
/ / Definitive Proxy Statement
/X/ Definitive Additional Materials
/ / Soliciting Material Under Rule 14a-12
RURAL/METRO CORPORATION
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)
ACCIPITER LIFE SCIENCES FUND, LP
ACCIPITER LIFE SCIENCES FUND II, LP
ACCIPITER LIFE SCIENCES FUND (OFFSHORE), LTD.
ACCIPITER LIFE SCIENCES FUND II (OFFSHORE), LTD.
ACCIPITER LIFE SCIENCES FUND II (QP), LP
CANDENS CAPITAL, LLC
ACCIPITER CAPITAL MANAGEMENT, LLC
GABE HOFFMAN
NICOLE VIGLUCCI
MOHSIN Y. MEGHJI
- --------------------------------------------------------------------------------
(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)
-1-
Payment of Filing Fee (Check the appropriate box):
/X/ No fee required.
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
(1) Title of each class of securities to which transaction applies:
- --------------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
- --------------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
- --------------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
- --------------------------------------------------------------------------------
(5) Total fee paid:
- --------------------------------------------------------------------------------
/ / Fee paid previously with preliminary materials:
- --------------------------------------------------------------------------------
/ / Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement number,
or the form or schedule and the date of its filing.
(1) Amount previously paid:
- --------------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
- --------------------------------------------------------------------------------
-2-
(3) Filing Party:
- --------------------------------------------------------------------------------
(4) Date Filed:
Accipiter Life Sciences Fund, LP ("ALS Fund"), together with the other
participants named herein, is filing materials contained in this Schedule 14A
with the Securities and Exchange Commission ("SEC") in connection with the
solicitation of proxies for the election of a slate of director nominees at the
2007 annual meeting of stockholders (the "Annual Meeting") of Rural/Metro
Corporation, a Delaware corporation (the "Company"). ALS Fund has not yet filed
a proxy statement with the SEC with regard to the Annual Meeting
Item 1: On September 11, 2007, Accipiter Capital Management, LLC issued the
following press release:
NEWS RELEASE
FOR IMMEDIATE RELEASE
ACCIPITER CAPITAL MANAGEMENT EXPRESSES CONCERN OVER RURAL/METRO'S FAILURE TO
RELEASE FOURTH QUARTER AND FISCAL YEAR END FINANCIAL RESULTS
NEW YORK, NEW YORK, SEPTEMBER 11, 2007 - Accipiter Capital Management
expressed its concern today over Rural/Metro Corporation's (Nasdaq: RURL) lack
of communication with stockholders regarding the Company's fourth quarter and
fiscal year end financial results.
Gabe Hoffman, Managing Member of Accipiter Capital Management, stated
"Accipter, a long-term, major stockholder owning nearly 15% of the outstanding
shares of Rural, is concerned with the Company's lack of communication with
stockholders regarding its release of fourth quarter and fiscal year end
financial numbers. At the end of July, Rural issued a press release trumpeting
the success of its short-term internal initiatives and indicating its intent to
hold a management-hosted conference call to discuss Rural's fourth quarter and
fiscal year end results. However, it is now less than two days from the SEC
filing deadline, and stockholders have been treated to nothing but silence, not
even call-in details for management's conference call. We demand that Rural
promptly inform stockholders of its plans to report fourth quarter and fiscal
year end results, as well as inform stockholders of any potential plans to file
for an extension on its 10-K filing"
# # #
Contacts
Dan Burch / Dan Sullivan
MacKenzie Partners, Inc.
212-929-5940 / 1-800-322-2885
-3-
CERTAIN INFORMATION CONCERNING PARTICIPANTS
Accipiter Life Sciences Fund, LP ("ALS Fund"), together with the other
Participants (as defined below), intend to make a preliminary filing with the
Securities and Exchange Commission ("SEC") of a proxy statement and accompanying
proxy card to be used to solicit votes for the election of a slate of director
nominees at the 2007 annual meeting of stockholders of Rural/Metro Corporation,
a Delaware corporation (the "Company").
ALS FUND ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT
WHEN IT IS AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY
STATEMENT WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT
HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THE SOLICITATION WILL
PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE UPON REQUEST. REQUESTS FOR
COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR, MACKENZIE
PARTNERS, INC. BY TELEPHONE AT 800-322-2885 OR EMAIL AT
PROXY@MACKENZIEPARTNERS.COM.
The participants in the proxy solicitation are anticipated to be Accipiter
Life Sciences Fund (Offshore), Ltd., ("ALS Fund Offshore"), Accipiter Life
Sciences Fund II, LP, ("ALS Fund II"), Accipiter Life Sciences Fund II
(Offshore), Ltd., ("ALS Fund II Offshore"), Accipiter Life Sciences Fund II
(QP), LP, ("ALS Fund II QP") (together with ALS Fund, ALS Fund Offshore, ALS
Fund II, ALS Fund II Offshore, ALS Fund II QP, the "Accipiter Entities"),
Accipiter Capital Management, LLC, ("Accipiter Management"), Candens Capital,
LLC, ("Candens Capital"), Gabe Hoffman, Nicole Viglucci and Mohsin Y. Meghji. As
of the date of this filing, ALS Fund, ALS Fund II and ALS Fund II QP
beneficially owned 745,595, 534,951 and 611,901 shares of Common Stock of the
Company, respectively. As the general partner of each of ALS Fund, ALS Fund II
and ALS Fund II QP, Candens Capital may be deemed to beneficially own the
1,892,447 shares of Common Stock of the Company collectively owned by ALS Fund,
ALS Fund II and ALS Fund II QP.
As of the date of this filing, ALS Fund Offshore and ALS Fund II Offshore
beneficially owned 749,867 and 1,059,333 shares of Common Stock of the Company,
respectively. As the investment manager of each of ALS Fund Offshore and ALS
Fund II Offshore, Accipiter Management may be deemed to beneficially own the
1,809,200 shares of Common Stock of the Company collectively owned by ALS Fund
Offshore and ALS Fund II Offshore.
As of the date of this filing Mr. Hoffman may be deemed to beneficially own
3,701,647 shares of Common Stock collectively owned by the Accipiter Entities.
Mr. Hoffman has sole voting and dispositive power with respect to the 3,701,647
Shares owned by the Accipiter Entities. Each of Candens Capital, Accipiter
Management and Gabe Hoffman disclaims beneficial ownership of the shares of
Common Stock of the Company owned by the Accipiter Entities except to the extent
of its or his pecuniary interest therein. Currently, neither Nicole Viglucci nor
Mohsin Y. Meghji beneficially owns any shares of Common Stock of the Company.
-4-
